Array BioPharma Inc. announced the completion of both the binimetinib and encorafenib definitive agreements with Novartis.
INDIANA UNIVERSITY School of Medicine and Lilly USA have partnered to form a medical student rotation program focused on drug development. The four-week program is available to third- and fourth-year students.
Amgen launched the Neulasta (pegfilgrastim) Delivery Kit in the U.S.
Bristol-Myers Squibb Co. and Bavarian Nordic formed an agreement providing Bristol-Myers Squibb an exclusive option to license and commercialize Prostvac, Bavarian Nordic's investigational phase III prostate-specific antigen targeting immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer, in a deal worth up to $975 million.
ANDREW ROBBINS was appointed chief operating officer of Array BioPharma Inc.
AbbVie announced a definitive agreement to acquire Pharmacyclics and its flagship asset Imbruvica for $21 billion. Under the terms of the transaction, announced March 4, AbbVie will pay$261.25 per share, comprised of a mix of cash and AbbVie equity.
PHILLIP SHARP was awarded the 2015 Othmer Gold Medal by the Chemical Heritage Foundation.
FDA launched a mobile application designed to speed public access to information about drug shortages. The app identifies current drug shortages, resolved shortages and discontinuations of drug products.
Silvia Formenti appointed chair of Department of Radiation Oncology at Weill Cornell Medical College
SILVIA FORMENTI was appointed chair of the Department of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at New York-Presbyterian/Weill Cornell Medical Center, effective April 15.
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion to extend the marketing authorization for Vectibix (panitumumab) to include combination with FOLFIRI as first-line treatment in adult patients with wild-type RAS metastatic colorectal cancer.
